Compare Johnson & Johnson (JNJ) vs Standard Lithium Ltd (SLI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Johnson & Johnson vs Standard Lithium Ltd — how do they compare? Johnson & Johnson trades at $261.44 (market cap $618.09B), while Standard Lithium Ltd trades at $1.58 (market cap $398.07M). The key difference: Johnson & Johnson is far larger — about 1552.7× Standard Lithium Ltd's market cap, and Johnson & Johnson pays a 2.09% dividend while Standard Lithium Ltd pays none. Which is the better fit depends on your goals — on Pluang, investors hold Johnson & Johnson for 129 Days and Standard Lithium Ltd for 23 Days on average.
| JNJ | SLI | |
|---|---|---|
Market Cap | $618.09B | $398.07M |
Volume | 6,050,983 | 1,564,155 |
Sector | Health | Basic Materials |
52-Week High | $278.43 | $5.65 |
52-Week Low | $186.00 | $1.61 |
Typical Hold Time | 129 Days | 23 Days |
Enterprise Value | $646.37B | $260.98M |
Dividend Yield | 2.09% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Johnson & Johnson (JNJ) trades at $256.48, down 0.76% today, with a bearish technical signal despite recent earnings beats. The stock shows strong fundamentals with 28.45% net profit margin and consistent revenue growth to $94.19B in 2025. Analyst consensus remains positive with a $286.53 price target, though technical indicators show resistance at $258 and support at $253. Recent news highlights pipeline strength including Icotyde's $4.5B peak sales potential (Bank of America, 2026-09-29).
JNJ presents a compelling long-term investment with diversified healthcare exposure and dividend stability, though near-term technical weakness and patent cliff concerns warrant caution. The 52.5% buy rating from analysts reflects confidence in innovation pipeline, while debt-to-asset ratio increase to 24.06% merits monitoring. Upside potential exists if Q3 earnings beat expectations on October 13.
Standard Lithium (SLI) trades at $1.58, down 4.24% today, with a bearish technical signal but bullish oscillators. The company shows negative profitability metrics with ROE at -15.55% and net income of -$48.40M for 2025, though recent quarterly EPS have beaten expectations. Positive developments include progress toward a final investment decision for the South West Arkansas lithium project by end of 2026 and expanded offtake agreements.
The outlook is mixed: analyst consensus is strongly bullish with a $3.83 price target (142% upside), but execution risks remain high as the company transitions to production. Key risks include project delays, funding needs, and negative cash flow from operations. The stock offers high potential reward but requires careful risk assessment given pre-revenue status.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →About Standard Lithium Ltd
Standard Lithium Ltd. is a company focused on the development of lithium projects in North America, with a primary focus on extracting lithium from brine resources. Their flagship projects aim to utilize proprietary, advanced direct lithium extraction (DLE) technologies to produce high-purity lithium compounds in an environmentally responsible manner. The company seeks to become a key domestic supplier to the growing electric vehicle and battery storage markets.
Read more on SLI →
